Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Acinetobacter Infections - Pipeline Review, H2 2017 - Research and Markets

Research and Markets
Posted on: 18 Dec 17

The "Acinetobacter Infections - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Acinetobacter Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Acinetobacter Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acinetobacter Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Acinetobacter Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 3, 31 and 15 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 8 molecules, respectively.

Acinetobacter Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Acinetobacter Infections - Overview
  3. Acinetobacter Infections - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Acinetobacter Infections - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Acinetobacter Infections - Companies Involved in Therapeutics Development
  • Achaogen Inc
  • Acies Bio doo
  • Adenium Biotech ApS
  • Aridis Pharmaceuticals LLC
  • Atterx Biotherapeutics Inc
  • AvidBiotics Corp
  • Emergent BioSolutions Inc
  • Entasis Therapeutics Inc
  • Evaxion Biotech ApS
  • F. Hoffmann-La Roche Ltd
  • FOB Synthesis Inc
  • Hsiri Therapeutics LLC
  • LegoChem Biosciences Inc
  • Melinta Therapeutics Inc
  • Nosopharm SAS
  • Novabiotics Ltd
  • Peptilogics Inc
  • Pfizer Inc
  • Redx Pharma Plc
  • Sarepta Therapeutics Inc
  • Sealife PHARMA GMBH
  • Shionogi & Co Ltd
  • Techulon Inc
  • Tetraphase Pharmaceuticals Inc
  • Vaxdyn SL
  • Xellia Pharmaceuticals ApS

For more information about this report visit https://www.researchandmarkets.com/research/hn6hzk/acinetobacter?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20171218005992/en/

Business Wire
www.businesswire.com

Last updated on: 18/12/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.